JMP Securities Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)
JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Protagonist Therapeutics (PTGX – Research Report) today and set a price ...
JMP Securities Sticks to Their Buy Rating for Cytokinetics (CYTK)
JMP Securities analyst Jason Butler maintained a Buy rating on Cytokinetics (CYTK – Research Report) today and set a price target of $78.00.
news.stocktradersdaily1d
(JPST) Pivots Trading Plans and Risk Controls
This Jpmorgan Ultra-short Income Etf (NASDAQ: JPST) report was produced by Stock Traders Daily. Over the past 20 years our metholdology has been refined to help identify strategies for both individual ...